(Q43039677)

English

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

scientific article published in December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Richard E Nettles

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Min Gao

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Marc Bifano

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ellen Chung

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Anna Persson

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Thomas C Marbury

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ronald Goldwater

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Michael P DeMicco

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Maribel Rodriguez-Torres

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Apinya Vutikullird

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ernesto Fuentes

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Eric Lawitz

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Juan Carlos Lopez-Talavera

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Dennis M Grasela

14

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

1 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1956-1965

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24609

21 January 2018

Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24609

21 January 2018

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24609

21 January 2018

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24609

21 January 2018

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24609

21 January 2018

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24609

21 January 2018

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24609

21 January 2018

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24609

21 January 2018

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24609

21 January 2018

Hepatitis C virus NS5A: tales of a promiscuous protein

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24609

21 January 2018

Identifiers

10.1002/HEP.24609

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43039677&oldid=1590129750"